Pei Yuyao, Huang Ruoxin, Chang Feng, Hu Yuanhui, Versteeg Sarah, Zheng Yufen
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
School of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada.
Pharmacy (Basel). 2025 Jul 21;13(4):97. doi: 10.3390/pharmacy13040097.
(1) Background: Patient-centered care for individuals with breast cancer requires multidisciplinary cooperation to ensure the appropriate use of medication and prevent medication-related problems. Pharmaceutical care has been associated with improved adherence in breast cancer management, a factor linked to patient outcomes and mortality. This study aims to summarize and explore the provision and utilization of pharmaceutical services for breast cancer patients by pharmacists. (2) Methods: A scoping review was performed to assess the pharmacist's role in providing pharmaceutical services for patients with breast cancer. A comprehensive review of four databases (PubMed, Ovid Embase, Ovid International Pharmaceutical Abstracts, and Scopus) was completed between 1 January 2012 and 8 April 2025 according to PRISMA-ScR framework. (3) Results: A total of 46 articles met the inclusion criteria, which included RCTs, observatory studies, cohort studies, and reviews. Findings suggest that both clinical and community pharmacists play an important role in prevention, management, and education for breast cancer patients. (4) Conclusions: Pharmacists can improve health outcomes by providing pharmaceutical service in breast cancer care. Optimizing interventions, expanding services, and evaluating long-term cost-effectiveness is needed in the future.
(1)背景:以患者为中心的乳腺癌患者护理需要多学科合作,以确保药物的合理使用并预防药物相关问题。药学服务与改善乳腺癌管理中的依从性相关,而依从性是与患者预后和死亡率相关的一个因素。本研究旨在总结和探讨药剂师为乳腺癌患者提供药学服务的情况及利用情况。(2)方法:进行了一项范围综述,以评估药剂师在为乳腺癌患者提供药学服务中的作用。根据PRISMA-ScR框架,于2012年1月1日至2025年4月8日对四个数据库(PubMed、Ovid Embase、Ovid国际药学文摘和Scopus)进行了全面检索。(3)结果:共有46篇文章符合纳入标准,包括随机对照试验、观察性研究、队列研究和综述。研究结果表明,临床药剂师和社区药剂师在乳腺癌患者的预防、管理和教育方面都发挥着重要作用。(4)结论:药剂师可以通过在乳腺癌护理中提供药学服务来改善健康结局。未来需要优化干预措施、扩大服务范围并评估长期成本效益。